Story perspectives

Novartis to Acquire Breast Cancer Drug for $3 Billion

3/21/2026

Summary

Story summary

Novartis AG will acquire SNV4818, a selective phosphoinositide 3-kinase alpha (PI3K?) inhibitor, from Synnovation Therapeutics for up to $3 billion (a $2 billion upfront payment and up to $1 billion in milestones).
SNV4818 targets the mutated PI3K? in HR+/HER2- breast cancer to improve tolerability by sparing normal cells.
The deal is expected to close in the first half of 2026, pending regulatory approvals.

History

Historical Context

The FDA approved idelalisib, the first PI3K inhibitor, in July 2014, revolutionizing cancer treatment by targeting specific cancer pathways. Novartis AG's recent $3 billion acquisition of SNV4818 from Synnovation Therapeutics underscores the growing investment in precision medicine, particularly for HR+/HER2- breast cancer, aiming to improve patient outcomes by minimizing damage to healthy cells and shifting treatment paradigms towards personalized approaches.

1 of 2

Story summary

Novartis AG will acquire SNV4818, a selective phosphoinositide 3-kinase alpha (PI3K?) inhibitor, from Synnovation Therapeutics for up to $3 billion (a $2 billion upfront payment and up to $1 billion in milestones).
SNV4818 targets the mutated PI3K? in HR+/HER2- breast cancer to improve tolerability by sparing normal cells.
The deal is expected to close in the first half of 2026, pending regulatory approvals.

1 / 2